Variable | ODX Not Given (n = 4118) | ODX Given (n = 1512) | Total (n = 5630) | P-Value |
---|---|---|---|---|
Patient Age at Diagnosis (Years) | < 0.01** | |||
< 50 | 7870 (18.9%) | 317 (21.0%) | 1097 (19.5%) | |
50–59 | 974 (23.7%) | 447 (29.6%) | 1421 (25.2%) | |
60–69 | 1166 (28.3%) | 518 (34.3%) | 1684 (29.9%) | |
> 69 | 1198 (29.1%) | 230 (15.2%) | 1428 (25.4%) | |
Marital Status | < 0.01** | |||
Single | 1620 (39.3%) | 464 (30.7%) | 2084 (37.0%) | |
Married | 2391 (58.1%) | 1010 (66.8%) | 3401 (60.4%) | |
Unknown | 107 (2.6%) | 38 (2.5%) | 145 (2.6%) | |
Payer | < 0.01** | |||
Self-Pay | 86 (2.1%) | 18 (1.2%) | 104 (1.8%) | |
Public | 1901 (46.2%) | 516 (34.1%) | 2417 (42.9%) | |
Private | 1659 (40.3%) | 790 (52.2%) | 2449 (43.5%) | |
Unknown | 472 (11.5%) | 188 (12.4%) | 660 (11.7%) | |
Year of Diagnosis | 0.14 | |||
2010 | 526 (12.8%) | 172 (11.4%) | 698 (12.4%) | |
2011 | 577 (14.0%) | 198 (13.1%) | 775 (13.8%) | |
2012 | 528 (12.8%) | 185 (12.2%) | 713 (12.7%) | |
2013 | 580 (14.1%) | 189 (12.5%) | 769 (13.7%) | |
2014 | 613 (14.9%) | 242 (16.0%) | 855 (15.2%) | |
2015 | 668 (16.2%) | 269 (17.8%) | 937 (16.6%) | |
2016 | 626 (15.2%) | 257 (17.0%) | 883 (15.7%) | |
Tumor Size (mm) | < 0.01** | |||
0.1–19 | 2390 (58.0%) | 1023 (67.7%) | 3413 (60.6%) | |
20–39 | 981 (23.8%) | 417 (27.6%) | 1398 (24.8%) | |
> 40 | 627 (15.2%) | 64 (4.2%) | 691 (12.3%) | |
Unknown | 120 (2.9%) | 8 (0.5%) | 128 (2.3%) | |
Tumor Grade | < 0.01** | |||
I | 854 (20.7%) | 398 (26.3%) | 1252 (22.2%) | |
II | 1719 (41.7%) | 844 (55.8%) | 2563 (45.5%) | |
III / IV | 1403 (34.1%) | 265 (17.5%) | 1668 (29.6%) | |
Unknown | 142 (3.4%) | 5 (0.3%) | 147 (2.6%) | |
LN Status | < 0.01** | |||
Negative | 2289 (55.6%) | 1196 (79.1%) | 3485 (61.9%) | |
Positive | 1257 (30.5%) | 284 (18.8%) | 1541 (27.4%) | |
Unknown | 572 (13.9%) | 32 (2.1%) | 604 (10.7%) | |
ER/PR/HER2 Status | < 0.01** | |||
HR+/HER2- | 2663 (64.7%) | 1446 (95.6%) | 4109 (73.0%) | |
Other | 1270 (30.8%) | 41 (2.7%) | 1311 (23.3%) | |
Unknown | 185 (4.5%) | 25 (2.5%) | 210 (3.7%) | |
Clinical Stage | < 0.01** | |||
1 | 2152 (52.3%) | 1034 (68.4%) | 3186 (56.6%) | |
2 | 1166 (28.3%) | 453 (30.0%) | 1619 (28.8%) | |
3 / 4 | 800 (19.4%) | 25 (1.7%) | 825 (14.7%) | |
ODX Eligiblea | 1472 (35.7%) | 1132 (74.9%) | 2604 (46.3%) | < 0.01** |
MD Gender | 0.34 | |||
Female | 2212 (53.7%) | 790 (52.2%) | 3002 (53.3%) | |
Male | 1906 (46.3%) | 722 (47.8%) | 2628 (46.7%) | |
MD Clinical Experience (Years) | 0.08 | |||
< 10 | 169 (4.1%) | 58 (3.8%) | 227 (4.0%) | |
10–19 | 1774 (43.1%) | 604 (39.9%) | 2378 (42.2%) | |
20–29 | 1254 (30.5%) | 511 (33.8%) | 1765 (31.3%) | |
> 29 | 921 (22.4%) | 339 (22.4%) | 1260 (22.4%) | |
Surgical Specialty | 0.72 | |||
General Surgeon | 3582 (87.0%) | 1309 (86.6%) | 4891 (86.9%) | |
Surgical Oncologist | 536 (13.0%) | 203 (13.4%) | 739 (13.1%) |